Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA

May 15, 2017
NEW HAVEN, Conn., May 15, 2017 /PRNewswire/ -- (NYSE: BHVN) -- Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) announced today that the U.S. Food and Drug Administration (FDA) has granted the company Fast…
READ MORE

Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors

May 15, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced today that the…
READ MORE

Loxo Oncology Announces Enrollment of First Patient in Phase 1 Clinical Trial for Highly Selective RET Inhibitor, LOXO-292

May 10, 2017
STAMFORD, Conn., May 10, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that…
READ MORE